Travis Steed
Stock Analyst at B of A Securities
(2.75)
# 1,792
Out of 5,142 analysts
92
Total ratings
46.48%
Success rate
6.45%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Upgrades: Neutral | $15 → $30 | $28.26 | +6.16% | 3 | Feb 20, 2026 | |
| BBNX Beta Bionics | Maintains: Buy | $30 → $33 | $13.76 | +139.83% | 1 | Jan 5, 2026 | |
| PEN Penumbra | Maintains: Buy | $320 → $370 | $339.20 | +9.08% | 2 | Jan 5, 2026 | |
| BDX Becton, Dickinson and Company | Maintains: Neutral | $190 → $207 | $184.34 | +12.29% | 10 | Jan 5, 2026 | |
| CNMD CONMED | Maintains: Neutral | $65 → $52 | $45.38 | +14.59% | 5 | Dec 8, 2025 | |
| MASI Masimo | Initiates: Neutral | $162 | $175.25 | -7.56% | 1 | Nov 17, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $115.29 | +30.11% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $72.65 | +17.00% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $82.44 | +9.17% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $19.99 | +60.08% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $42 → $45 | $21.26 | +111.67% | 5 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $480 → $45 | $3.35 | +1,243.28% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $315 | $384.73 | -18.12% | 5 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $295 | $249.38 | +18.29% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $35.38 | -54.78% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $99.46 | +60.87% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $492.10 | -35.99% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $1.48 | +440.54% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $10.57 | +136.52% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $14.20 | +498.59% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $73.26 | +70.63% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $98.61 | +47.04% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $74.37 | -31.42% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $11.76 | +359.18% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $73.42 | -70.04% | 1 | Jul 17, 2017 |
Tandem Diabetes Care
Feb 20, 2026
Upgrades: Neutral
Price Target: $15 → $30
Current: $28.26
Upside: +6.16%
Beta Bionics
Jan 5, 2026
Maintains: Buy
Price Target: $30 → $33
Current: $13.76
Upside: +139.83%
Penumbra
Jan 5, 2026
Maintains: Buy
Price Target: $320 → $370
Current: $339.20
Upside: +9.08%
Becton, Dickinson and Company
Jan 5, 2026
Maintains: Neutral
Price Target: $190 → $207
Current: $184.34
Upside: +12.29%
CONMED
Dec 8, 2025
Maintains: Neutral
Price Target: $65 → $52
Current: $45.38
Upside: +14.59%
Masimo
Nov 17, 2025
Initiates: Neutral
Price Target: $162
Current: $175.25
Upside: -7.56%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $115.29
Upside: +30.11%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $72.65
Upside: +17.00%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $82.44
Upside: +9.17%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $19.99
Upside: +60.08%
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $21.26
Upside: +111.67%
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $3.35
Upside: +1,243.28%
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $384.73
Upside: -18.12%
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $249.38
Upside: +18.29%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $35.38
Upside: -54.78%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $99.46
Upside: +60.87%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $492.10
Upside: -35.99%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $1.48
Upside: +440.54%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $10.57
Upside: +136.52%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $14.20
Upside: +498.59%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $73.26
Upside: +70.63%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $98.61
Upside: +47.04%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $74.37
Upside: -31.42%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $11.76
Upside: +359.18%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $73.42
Upside: -70.04%